# Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
Canonical URL: https://biopharmsignal.com/news/TPST/tempest-to-advance-dual-targeting-car-t-platform-with-clinical-update-at-isct-2026-annual-meeting
Ticker: TPST
Company: Tempest Therapeutics
Source: Tempest Therapeutics
Published: 2026-04-29 12:00 EST
Original Source URL: https://ir.tempesttx.com
## Summary

Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate TPST-2003 Results support clinical benefit of parallel-structure dual-targeting CAR architecture in patients with relapsed/refractory multiple myeloma Data further

## Article Body
Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate TPST-2003 Results support clinical benefit of parallel-structure dual-targeting CAR architecture in patients with relapsed/refractory multiple myeloma Data further
## Recent Company News
- 2026-05-29 12:00 EST — [Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds](https://biopharmsignal.com/news/TPST/tempest-therapeutics-announces-warrant-exercise-for-approximately-2-million-in-gross-proceeds) — Source: Tempest Therapeutics
- 2026-05-14 20:15 EST — [Tempest Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/TPST/tempest-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Tempest Therapeutics
- 2026-05-06 11:00 EST — [Tempest Presents Clinical Update at ISCT 2026 Annual Meeting](https://biopharmsignal.com/news/TPST/tempest-presents-clinical-update-at-isct-2026-annual-meeting) — Source: Tempest Therapeutics
- 2026-04-29 12:00 EST — [Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting](https://biopharmsignal.com/news/TPST/tempest-to-advance-dual-targeting-car-t-platform-with-clinical-update-at-isct-2026-annual-meeting) — Source: Tempest Therapeutics
- 2026-04-22 12:00 EST — [Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T](https://biopharmsignal.com/news/TPST/tempest-announces-key-manufacturing-milestone-for-tpst-2003-dual-targeting-cd19-bcma-car-t) — Source: Tempest Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)